OverviewSuggest Edit
Neuronetics is a medical device company. It develops non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. In addition, the Company provides NeuroStar TMS Therapy (transcranial magnetic stimulation), a non-invasive form of neuromodulation.
| Type | Public | |
| Founded | 2003 | |
| HQ | Malvern, PA, US | Map |
| Website | neurostar.com |
Recent NewsAll News
Key People/Management at Neuronetics
Charles E. Larsen
Co-Founder
Mark A. Demitrack
Chief Medical Officer
Kevin Bitterman
Director
Mary Hailey
VP of Health Policy and Government Relations
Neuronetics Office Locations
Neuronetics has an office in Malvern
Malvern, PA, US (HQ)
31 General Warren Blvd
Neuronetics Financials and Metrics
Neuronetics Revenue
Neuronetics's revenue was reported to be $49.24 m in FY, 2020
| USD | |
|---|---|
Revenue (Q1, 2021) | 12.3m |
Gross profit (Q1, 2021) | 10.1m |
Gross profit margin (Q1, 2021), % | 81.9% |
Net income (Q1, 2021) | (7.9m) |
EBIT (Q1, 2021) | (6.9m) |
Market capitalization (11-Jun-2021) | 402.2m |
Closing stock price (11-Jun-2021) | 15.6 |
Cash (31-Mar-2021) | 121.3m |
EV | 316.3m |
Neuronetics's current market capitalization is $402.2 m.
Annual
Annual
Annual
Quarterly
| USD | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (13.0m) | (18.0m) | (7.5m) | (14.6m) | (21.5m) | (12.6m) | (20.4m) | (23.8m) | (7.9m) |
Depreciation and Amortization | 463.0k | 671.0k | 204.0k | 457.0k | 765.0k | 301.0k | 534.0k | 741.0k | 281.0k |
Inventories | (378.0k) | (767.0k) | 59.0k | (82.0k) | (455.0k) | (104.0k) | (557.0k) | (1.0m) | (1.7m) |
Accounts Payable | (89.0k) | (594.0k) | (1.5m) | (228.0k) | 10.0k | (1.3m) | (2.4m) | (2.3m) | (694.0k) |
| USD | Q2, 2018 |
|---|---|
EV/EBIT | -88.1 x |
EV/CFO | -34.4 x |
Revenue/Employee | 70.5k |
Debt/Equity | -0.1 x |
Debt/Assets | 1.1 x |
Financial Leverage | -0.1 x |
Neuronetics Cybersecurity Score
Neuronetics Environment, Social & Governance (ESG) Ratings
Neuronetics Online and Social Media Presence
1.15k Twitter followers
Neuronetics has 1.15k Twitter Followers. The number of followers has decreased 0.2% month over month and increased 0.1% quarter over quarter
Neuronetics's Trends
Twitter Engagement Stats for @TMSTherapy
752
Tweets
891
Following
1.1k
Followers
17
Tweets last 30 days
1.4
Avg. likes per Tweet
88.2%
Tweets with engagement
Neuronetics News and Updates
June 09, 2021
Neuronetics Unveils New Clinical Data at Clinical TMS Society 2021 Annual Meeting
The market leader in transcranial magnetic stimulation will spotlight real-world clinical data on NeuroStar® Advanced Therapy for Mental Health The market leader in transcranial magnetic stimulation will spotlight real-world clinical data on NeuroStar® Advanced Therapy for Mental Health
June 03, 2021
Neuronetics to Present at The JMP Securities Life Sciences Conference
MALVERN, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Su…
June 01, 2021
Neuronetics Names Todd Cushman as Vice President, Business Development
With this new appointment, the market leader in transcranial magnetic stimulation will continue expanding treatment access for patients with Major Depressive Disorder With this new appointment, the market leader in transcranial magnetic stimulation will continue expanding treatment access for patien…
May 20, 2021
Neuronetics to Present at the William Blair 41st Annual Growth Stock Conference
MALVERN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sul…
May 04, 2021
Neuronetics Reports First Quarter 2021 Financial and Operating Results
MALVERN, Pa., May 04, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial …
May 03, 2021
Neuronetics Employee Patient Advocates Honor Mental Health Awareness Month by Sharing Personal Depression Experiences
Employees who have found depression relief with NeuroStar Advanced Therapy for Mental Health use their voice to help others Employees who have found depression relief with NeuroStar Advanced Therapy for Mental Health use their voice to help others
Neuronetics Blogs
May 17, 2021
Neuronetics® Celebrates 100,000 Treatment Milestone for Southern California TMS Center
The market leader in transcranial magnetic stimulation therapy celebrates leading provider of NeuroStar Advanced Therapy for Mental Health MALVERN, Pa. , May 17, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing
January 12, 2021
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results
MALVERN, Pa. , Jan. 12, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today, in advance of the
December 08, 2020
Neuronetics Announces the Amendment of Credit Facility with Solar Capital Partners
Amendment provides Neuronetics with available and flexible funding options through 2022 MALVERN, Pa. , Dec. 08, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality
November 23, 2020
Neuronetics® Receives FDA Clearance for Three-Minute TouchStar™ Treatment Protocol
TouchStar theta burst protocol leverages NeuroStar® Advanced Therapy’s patented Contact Sensing technology to help ensure the optimum prescribed treatment dose to patients MALVERN, Pa. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology
November 02, 2020
Neuronetics Reports Third Quarter 2020 Financial and Operating Results
MALVERN, Pa. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial
October 19, 2020
Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call
MALVERN, Pa. , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics , Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it
Neuronetics Frequently Asked Questions
When was Neuronetics founded?
Neuronetics was founded in 2003.
Who are Neuronetics key executives?
Neuronetics's key executives are Charles E. Larsen, Mark A. Demitrack and Kevin Bitterman.
How many employees does Neuronetics have?
Neuronetics has 235 employees.
What is Neuronetics revenue?
Latest Neuronetics annual revenue is $49.2 m.
What is Neuronetics revenue per employee?
Latest Neuronetics revenue per employee is $209.5 k.
Who are Neuronetics competitors?
Competitors of Neuronetics include Tombot, Elevations RTC and Salience TMS Neuro Solutions.
Where is Neuronetics headquarters?
Neuronetics headquarters is located at 31 General Warren Blvd, Malvern.
Where are Neuronetics offices?
Neuronetics has an office in Malvern.
How many offices does Neuronetics have?
Neuronetics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies